Even though CSF-1R inhibition enhances TAMs’ ability to present antigens in animal models of aggressive pancreatic ductal adenocarcinoma, it may cause exhausted phenotypes of cytotoxic T cells, highlighting the importance of combining immune checkpoint inhibitors and CSF-1R inhibitors in treating these tumors (172). This evidence concerns the gene CSF1R and pancreatic ductal adenocarcinoma.